Molecular Partners AG
SIX:MOLN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.17
9.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Molecular Partners AG
Molecular Partners AG
Cash & Cash Equivalents
Molecular Partners AG
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Cash & Cash Equivalents
CHf65.7m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Cash & Cash Equivalents
$278.6m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Cash & Cash Equivalents
CHf32.4m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Cash & Cash Equivalents
$225.7m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Cash & Cash Equivalents
CHf63m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-7%
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Cash & Cash Equivalents
CHf13.7m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's Cash & Cash Equivalents?
Cash & Cash Equivalents
65.7m
CHF
Based on the financial report for Jun 30, 2024, Molecular Partners AG's Cash & Cash Equivalents amounts to 65.7m CHF.
What is Molecular Partners AG's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-1%
Over the last year, the Cash & Cash Equivalents growth was 4%. The average annual Cash & Cash Equivalents growth rates for Molecular Partners AG have been -20% over the past three years , -1% over the past five years .
You don't have any saved screeners yet
